Mapping a Path to
Breakthrough Therapies
Dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer
Discover the science
MDM2
KRT-232
p53
The MDM2-p53 interaction represents a compelling therapeutic target with potential to provide a new treatment option for patients with Myelofibrosis (MF), Polycythemia Vera (PV), Acute Myeloid Leukemia (AML), and Merkel Cell Carcinoma (MCC)
Navtemadlin (KRT-232)
A novel, potent, and selective oral MDM2 inhibitor
Active Clinical StudiesKRT-232
MDM2
